Abstract
Graves' disease (GD) is the most common cause of hyperthyroidism in countries with adequate iodine supply, and its main extrathyroid manifestation is thyroid orbitopathy. For many years, thyrotoxicosis has been treated with antithyroid drugs, radioactive iodine therapy and thyroidectomy, and glucocorticoids have remained the standard treatment of thyroid eye disease (TED). Currently, there is a growing trend of using targeted therapies in the treatment of thyroid orbitopathy (TO). The significant development of immunobiology, a better understanding of the pathophysiology of the disease and a multitude of studies on new therapies give hope for better treatment results and an improvement in the quality of life of patients.
The aim of the paper is to discuss the current principles of management of Graves' disease, including thyroid orbitopathy, with particular emphasis on new therapeutic methods. The potent role of K1-70TM and small molecule thyroid stimulating hormone (TSH) receptor antagonists in the treatment of hyperthyroidism is indicated. Not only do we point out the promising outcomes of combining glucocorticoids with mycophenolates, but also highlight the use of teprotumumab, rituximab, cyclosporin A, azathioprine, methotrexate, tocilizumab and sirolimus in the therapy of active moderate to severe form of orbitopathy. The protective and supportive effect of statins in the treatment of TED is noted. The limitations of the research results mentioned in the paper are remarked and the need for further randomized studies of long-term safety and efficacy in a larger group of patients is underlined.
References
(1) Mortara L, Coco G, Gatti L, et al. Analysis of Graves’ disease from the origins to the current historical evolution: The history of Graves’ disease discovery and treatment. Med Histor. 2022; 5(3):e2021030. Web sites. https://mattioli1885journals.com/index.php/MedHistor/article/view/12121.
(2) Jastrzębska H, Bednarczuk T, Kochman M Nadczynność tarczycy. [In:] Zgliczyński W. Endokrynologia – część pierwsza. Wielka Interna – 2nd ed. Medical Tribune, Warszawa 2020; 274-286.
(3) Antonelli A, Ferrari SM, Ragusa F, et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab 2020; 34(1):101387. DOI:10.1016/j.beem.2020.101387.
(4) Brix TH, Knudsen GP, Kristiansen M, et al. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab 2005; 90(11):5949-5953. DOI:10.1210/jc.2005-1366.
(5) Kossler AL, Douglas R, Dosiou C. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. J Clin Endocrinol Metab 2022; 107(Suppl 1):S36-S46. DOI:10.1210/clinem/dgac168.
(6) Hiromatsu Y, Eguchi H, Tani J, et al. Graves' ophthalmopathy: epidemiology and natural history. Intern Med 2014; 53(5):353--360. DOI:10.2169/internalmedicine.53.1518.
(7) Bahn RS. Current Insights into the Pathogenesis of Graves' Ophthalmopathy. Horm Metab Res 2015; 47(10):773-778. DOI:10.1055/s-0035-1555762.
(8) Diana T, Wüster C, Kanitz M, et al. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest 2016; 39(10):1159-1165. DOI:10.1007/s40618-016-0478-9.
(9) TJ, Janssen JAMJL. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. Endocr Rev 2019; 40(1):236-267. DOI:10.1210/er.2018-00066.
(10) Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 2020; 16(2):104-116. DOI:10.1038/s41574-019-0305-4.
(11) Smith TJ, Hoa N. Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004; 89(10):5076-5080. DOI:10.1210/jc.2004-0716.
(12) Jyonouchi SC, Valyasevi RW, Harteneck DA, et al. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy. Thyroid 2001; 11(10):929-934. DOI:10.1089/105072501753210984.
(13) Strianese D, Iuliano A, Ferrara M, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol 2014; 2128903, DOI:10.1155/2014/128903.
(14) Tomlinson JW, Durrani OM, Bujalska IJ, et al. The role of 11betahydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2010; 95:398-406. DOI:10.1210/jc.2009-0873.
(15) Cao J, Wang N, Luo Y, et al. A cause-effect relationship between Graves' disease and the gut microbiome contributes to the thyroid-gut axis: A bidirectional two-sample Mendelian randomization study. Front Immunol 2023; 14:977587. DOI:10.3389/fimmu.2023.977587.
(16) Bartalena L, Masiello E, Magri F, et al. The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest 2016; 39(12):1445-1451. DOI:10.1007/s40618-016-0516-7.
(17) Ippolito S, Cusini C, Lasalvia P, et al. Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest 2021; 44(8):1707-1718. DOI:10.1007/s40618-020-01479-z.
(18) Chin YH, Ng CH, Lee MH, et al. Prevalence of thyroid eye disease in Graves’ disease: a meta-analysis and systematic review. Clin Endocrinol (Oxf) 2020; 93(4):363-374. DOI:10.1111/cen.14296.
(19) Wiersinga WM. Management of Graves ophthalmopathy. Nat Clin Pract Endocrinol Metab 2007; 3:396-404. DOI:10.1038/ncpendmet0497.
(20) Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 2014; 37(8):691-700. DOI:10.1007/s40618-014-0097-2.
(21) Kahaly GJ. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. J Clin Endocrinol Metab 2020; 105(12):3704-3720. DOI:10.1210/clinem/dgaa646.
(22) Okamoto Y, Tanigawa S, Ishikawa K, et al. TSH receptor antibody measurements and prediction of remission in Graves’ disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 2006; 53(4):467-472. DOI:10.1507/endocrj.k05-121.
(23) Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 2018; 7(4):167-186. DOI:10.1159/000490384.
(24) Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 2013; 98(12):4776-4783. DOI:10.1210/jc.2013-2569.
(25) Bartalena L, Kahaly GJ, Baldeschi L, et al. EUGOGO †. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 2021; 185(4): G43-G67, DOI:10.1530/EJE-21-0479.
(26) Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26(10):1343-1421. DOI:10.1089/thy.2016.0229.
(27) Jastrzębska H. Zachowawcze leczenie łagodnych chorób tarczycy. [In:] Zgliczyński W. Endokrynologia – część pierwsza. Wielka Interna – 2nd ed. Medical Tribune, Warszawa 2020; 250-251.
(28) Gronich N, Lavi I, Rennert G, et al. Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid 2020; 30(2):243-250. DOI:10.1089/thy.2019.0205.
(29) Furmaniak J, Sanders J, Sanders P, et al. TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial. Clin Endocrinol (Oxf) 2022; 96(6):878-887. DOI:10.1111/cen.14681.
(30) Lane LC, Cheetham TD, Perros P, et al. New Therapeutic Horizons for Graves' Hyperthyroidism. Endocr Rev 2020; 41(6):873-884. DOI:10.1210/endrev/bnaa022.
(31) Karstens WFJ, Menge W M B P, Martens G, et al. Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist, Bioorg Med Chem 2023; 84:117258. DOI:10.1016/j.bmc.2023.117258.
(32) Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997; 47(1):9-14. DOI:10.1046j.1365-2265.1997.2331047.x. Erratum [in:] Clin Endocrinol (Oxf) 1997; 47(5):632. PMID: 9302365.
(33) Nowak M, Marek B, Kos-Kudła B, et al. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO). Endokrynol Pol 2022; 73(4):756-777. DOI:10.5603/EP.a2022.0040.
(34) Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013; 98:1443-1449. DOI:10.1210/jc.2012-3873.
(35) Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 1977; 44(1):203-204; DOI:10.1210/jcem-44-1-203.
(36) Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves’ orbitopathy. J Endocrinol Invest 2021; 44(4):703-712. DOI:10.1007/s40618-020-01380-9.
(37) Tsai CC, Cheng CY, Liu CY, et al. Oxidative stress in patients with Graves’ ophthalmopathy: relationship between oxidative DNA damage and clinical evolution. Eye (Lond) 2009; 23(8):1725-1730. DOI:10.1038/eye.2008.310.
(38) Cawood TJ, Moriarty P, O’Farrelly C, et al. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab 2007; 92(1):59-64. DOI:10.1210/jc.2006-1824.
(39) Marcocci C, Kahaly GJ, Krassas GE, et al. European Group on Graves’ Orbitopathy. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011; 364(20):1920-1931. DOI:10.1056/NEJMoa1012985.
(40) Zhu W, Ye L, Shen L, et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves’ ophthalmopathy. J Clin Endocrinol Metab 2014; 99(6):1999-2007. DOI:10.1210/jc.2013-3919.
(41) Zhang L, Grennan-Jones F, Draman MS, et al. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. J Clin Endocrinol Metab 2014; 99(7):E1183-90. DOI:10.1210/jc.2013-4182.
(42) Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47(2-3):85-118. DOI:10.1016/s0162-3109(00)00188-0.
(43) Kahaly GJ, Riedl M, König J, et al. European Group on Graves’ Orbitopathy (EUGOGO). Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 2018; 6(4):287-298, DOI:10.1016/S2213-8587(18)30020-2.
(44) Lee ACH, Riedl M, Frommer L, et al. Systemic safety analysis of mycophenolate in Graves’ orbitopathy. J Endocrinol Invest 2020; 43(6):767-777. DOI:10.1007/s40618-019-01161-z.
(45) Chen H, Shan SJ, Mester T, et al. TSH-mediated TNFα production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist. PLoS One 2015; 10(6):e0130322. DOI:10.1371/journal.pone.0130322.
(46) Supronik J, Szelachowska M, Kretowski A, et al. Rituximab in the treatment of Graves' orbitopathy: latest updates and perspectives. Endocr Connect 2022; 11(12):e220303. DOI:10.1530/EC-22-0303.
(47) Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986; 16(5):415-422. DOI:10.1111/j.1365-2362.1986.tb01016.x.
(48) Shen L, Ye L, Zhu W, et al. Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves’ orbitopathy. Eur Thyroid J. 2022;11(5):e220017. DOI:10.1530/ETJ-22-0017.
(49) Moi L, Hamedani M, Ribi C. Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab. Clin Endocrinol (Oxf) 2022; 97(3):363-370. DOI:10.1111/cen.14655.
(50) Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. J Clin Med 2021; 10(4):706. DOI:10.3390/jcm10040706.
(51) Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. J Clin Med 2020; 9(9):2816. DOI:10.3390/jcm9092816.
(52) Lanzolla G, Maglionico MN, Comi S, et al. Sirolimus as a second-line treatment for Graves' orbitopathy. J Endocrinol Invest 2022; 45(11):2171-2180. DOI:10.1007/s40618-022-01862-y.
(53) Koch CA, Krabbe S, Hehmke B. Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties? Rev Endocr Metab Disord 2018; 19(4):363-395. DOI:10.1007/s11154-018-9478-8.
(54) Nilsson A, Tsoumani K, Planck T. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease. J Clin Endocrinol Metab 2021; 106(5):1325-1332. DOI:10.1210/clinem/dgab070.
(55) Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Tocilizumab in Graves Orbitopathy Study Group. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 2018; 195(1):181-190. DOI:10.1016/j.ajo.2018.07.038.
(56) Stein JD, Childers D, Gupta S, et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 2015; 133(3):290-296. DOI:10.1001/jamaophthalmol.2014.5103.
(57) Lanzolla G, Sabini E, Leo M, et al. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol 2021; 9(11):733-742. DOI:10.1016/S2213-8587(21)00238-2.
(58) Tramunt B, Imbert P, Grunenwald S, et al. Sight-threatening Graves’ orbitopathy: Twenty years’ experience of a multidisciplinary thyroid-eye outpatient clinic. Clin Endocrinol 2019. 90(1):208-213. DOI:10.1111/cen.13880.
This work is licensed under a Creative Commons Attribution 4.0 International License.